Business Context and Reporting Period
Company: Ekso Bionics Holdings, Inc. (Note: Input metadata referenced "Chronoscale Corp," but the filing text identifies Ekso Bionics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2024
Reporting Period: Event-based report regarding a Nasdaq listing deficiency notice received on December 12, 2024.
Key Financial Metrics
This filing is a notice of a listing deficiency and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
- Stock Price Deficiency: The Company's common stock closing bid price has been below the $1.00 per share minimum requirement for the last 31 consecutive business days.
- Regulatory Action: Received a written notice from Nasdaq Listing Qualifications staff regarding failure to satisfy Nasdaq Listing Rule 5550(a)(2).
Guidance, Outlook, and Risks
- Compliance Period: The Company has an initial 180-day period (until June 10, 2025) to regain compliance.
- Compliance Criteria: To regain compliance, the closing bid price must be $1.00 or more for a minimum of ten consecutive business days before June 10, 2025.
- Future Options: If compliance is not met by June 10, 2025, the Company may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and potentially effects a reverse stock split.
- Delisting Risk: Failure to regain compliance during the second period could result in delisting, subject to appeal.
- Management Intent: The Company intends to actively monitor the stock price and consider available options to regain compliance.
- Forward-Looking Statements: No assurance is given that the Company will regain compliance or avoid delisting.
Investor Verification Checklist
- Verify the current closing bid price of EKSO stock relative to the $1.00 threshold.
- Monitor the Company's stock price for ten consecutive days of $1.00 or higher to confirm compliance.
- Review the Company's 10-K and 10-Q filings for financial health and market value of publicly held shares (required for a potential second compliance period).
- Watch for announcements regarding a potential reverse stock split if the initial compliance period expires without success.
- Confirm the status of the listing on the Nasdaq Capital Market as of June 10, 2025.